Drugs
Bioterrorism, drug preparedness and natural disaster response
Drug Approvals and DatabasesDrug-Related Databases from FDA; Information on Drug Approvals
Drug Safety and AvailabilityMedication Guides, Drug Shortages, Public Health Advisories and Other Safety Announcements
Development & Approval Process (Drugs)Conducting Clinical Trials, Types of Drug Applications, Forms and Submissions Requirements, Labeling Initiatives
Guidance for Industry, Warning Letters, Postmarket Surveillance Programs
News & EventsWhat's New on This Site, Drug Approval Listing, Meetings and Conferences
Science & Research (Drugs)Research by FDA Staff to Evaluate and Enhance the Safety of Drug Products
Resources for YouFor Consumers, Health Professionals, Industry
News and Announcements
- Early Communication about an Ongoing Safety Review of Meridia (sibutramine hydrochloride)
- Information for Healthcare Professionals: Peramivir IV Renal Dosing Recommendations
- Vicks Sinex Nasal Spray - Recall
Product found containing the bacteria B. cepacia. Posted 11/19/2009 - Public Health Advisory: Updated Safety Information about a drug interaction between Clopidogrel Bisulfate (marketed as Plavix) and Omeprazole (marketed as Prilosec and Prilosec OTC)
Drug Safety
Spotlight
- Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV (PDF - 114KB)
- FDA Public Health Alert: Potential Medication Errors with Tamiflu for Oral Suspension
- Drugs@FDA
- Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
- National Drug Code Directory
Recalls & Alerts
Stay Informed
Contact Us
Human Drug Information
- (888) 463-6332
- (301) 796-3400
- druginfo@fda.hhs.gov
Division of Drug Information (CDER)
Office of Training and Communication
WO51-2201
10903 New Hampshire Avenue
Silver Spring, MD 20993